Study on people with EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at real-world treatment for non-small cell lung cancer with a specific genetic change (EGFR mutation). It might help researchers understand how different treatments work in daily practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (stage IIIB or IV) that cannot be removed by surgery.
- Your cancer has an EGFR mutation, confirmed between July 2018 and March 2022.
- You were diagnosed and treated at one of the participating centers.
- You did not receive cancer treatment outside of the study center.
- You have not had another type of cancer in the last 5 years (except certain skin cancers).
- You have not taken part in any other clinical trials during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses leftover tissue samples from people with EGFR-mutant non-small cell lung cancer to test how well different drugs work against their tumor cells. It may help guide future treatment decisions.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This trial collects information from people with a specific type of advanced lung cancer to create a comparison group. It helps researchers understand how well new treatments work without giving any experimental medicine.
This study tests if regular blood tests can help guide chemotherapy treatment before surgery for people with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It aims to see if these blood tests can show how well the cancer is responding, potentially allowing doctors to adjust treatment for better outcomes.
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.